Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.64 |
| ▸ | PIM1 | P11309 | 7/20 | 0.64 |
| ▸ | GSK3B | P49841 | 7/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780205 | 0.86 | PIK3CD (0.64) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL1251737 | 0.85 | PIK3CD (0.73) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL1779629 | 0.85 | PIK3CD (0.62) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL458969 | 0.83 | PIK3CA (0.66) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL12603576 | 0.81 | PIK3CD (0.78) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL1251809 | 0.81 | PIK3CD (0.78) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL1779248 | 0.81 | PIK3CD (0.69) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL1251740 | 0.81 | PIK3CD (0.76) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL457079 | 0.81 | PIK3CD (0.76) | PIK3CDPIK3CBPIK3CAPIM1GSK3B | |
| SCHEMBL1250145 | 0.81 | PIK3CD (0.76) | PIK3CDPIK3CBPIK3CAPIM1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765743-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-01 | — | — | US | claimed |
| US-20110118246-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-19 | — | — | US | claimed |
| EP-2280959-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | claimed |
| WO-2009147190-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-8765743-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-01 | — | — | US | disclosed |
| US-8765743-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-01 | — | — | US | disclosed |
| US-8765743-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-01 | — | — | US | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20110118246-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-19 | — | — | US | disclosed |
| US-20110118246-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-19 | — | — | US | disclosed |
| US-20110118246-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-19 | — | — | US | disclosed |
| EP-2280959-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009147190-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CB 1706/4885PIK3CA 2691/4885 |
| US-20110118246-A1 | Novel Compounds | PIK3CA, PIK3C2B, PIK3CD | PIK3CD 3/4885PIK3CB 4/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.